Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Trial Profile

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Nov 2016 New trial record
    • 01 Nov 2016 Results assessing Incidence of thyroid-related adverse events published in the Journal of Clinical Endocrinology and Metabolism
    • 11 Oct 2016 Results assessing the correlation between baseline characteristics and outcome of patients treated outside of clinical trial (n=288) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top